What is JBIO's free cash flow yield?

JBIO (JBIO) reported free cash flow yield of -12.5% in Q4 2025.

What does free cash flow yield mean?

Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.

JBIO JBIO Free cash flow yield

Free cash flow yield at other companies

Vertex PharmaceuticalsVRTX

3.3%+2.2pp

Climb Global Solutions, Inc.CLMB

10.6%—

Travere Therapeutics, Inc.TVTX

-25.1%-6.6pp

Vera TherapeuticsVERA

-10.2%0.0pp

AnaptysBio, Inc.ANAB

0.3%+0.1pp

Avalo TherapeuticsAVTX

-63.1%-29.0pp

Other financials

Income statement

See full

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

See full

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

See full

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

See full

Market cap$1.33B+316%

Enterprise value$1.27B—

Returns & leverage

See full

Return on equity-132.5%+120pp

Debt / equity0×—

Current ratio14.3×-17.7×

Where this comes from

Calculated from JBIO’s reported figures.

free cash flow/market cap=-12.5%

Based on trailing twelve months.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is JBIO's free cash flow yield?: JBIO (JBIO) reported free cash flow yield of -12.5% in Q4 2025.
What does free cash flow yield mean?: Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.